ProPhase Labs : Full ProPhase Labs Presentation as of 6.11.24
June 12, 2024 at 03:33 pm EDT
Share
Investor Presentation
2012
2017
2018
Q4 2020
2021
Ted Karkus, CEO, restructures and turns around the Company. Ultimately revenue grew to a peak of $122 million for the FY2022 vs $22 million for FY2012.
Sold the Cold-EEZE cold remedy brand for $50m to Mylan Pharmaceuticals.
From 2018 to 2022 we delivered shareholder value through special dividends of $2.40 per share cumulatively over 4 years.
We commenced CLIA lab services and have transitioned from COVID-19 testing to genomic sequencing in our CLIA lab, which represents significant upside.
Acquisition of Nebula Genomics. Plan to leverage Food, Drug and Mass distribution and genomic sequencing in CLIA labs. Significant upside.
2024
Q4 2023
Q1 2023
Q4 2022
Q2 2022
We began our expansion plan of Pharmaloz in 2024, and the new equipment delivered is expected to double current capacityFN. A second lozenge line is expected to be installed by midyear 2024 increasing capacity to $30- $35MFN.
We opened a world class whole genome sequencing (WGS) lab in Garden City, NY. This includes 4 leading platforms of WGS equipment and allows for the ability to build a B2B WGS business offering exceptionally low prices.
Reported FY 2022 results - Net Revenue: $122.6M, Net Income: $18.5M, Adjusted EBITDA: $38.6M
We acquired worldwide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets.
We exclusively licensed two potential broad based anti-virals, Equivir (Dietary Supplement) and Equivir G (Rx)
See Appendix A for Adjusted EBITDA reconciliation.
Management's analysis and guidance announced by ProPhase Labs on January 23, 2024: https://www.globenewswire.com/en/news-release/2024/01/23/2814037/0/en/Pharmaloz-Manufacturing-Accelerates-Expansion-Improves-Pricing-Boosts-Profitability-and-Secures-New-Contracts.html
26
26
A line of dietary supplements dedicated to providing clinically tested products for men's sexual health that we develop and market.
Mission: To usher in the era of personal genomics by providing access to affordable and secure Whole Genome Sequencing.
"Genome sequencing is like the internet back in the late 1980s."
Attachments
Original Link
Original Document
Permalink
Disclaimer
ProPhase Labs Inc. published this content on
12 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
12 June 2024 19:32:05 UTC.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
